SBIR/STTR BRIDGE FUNDING & ADDF/NIH FUNDING OPPORTUNITIES

Funding Agency:
Alzheimer’s Drug Discovery Foundation

The ADDF works with the National Institute of Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS) to provide additional funding opportunities for applicants and grantees.

1. The ADDF provides funding to US-based companies that were awarded Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) grants from the NIA and need bridge funding to obtain additional data in support of an SBIR/STTR-Phase 2 grant or for other NIH grants. Receiving interim funding from ADDF will also enable investigators to continue to generate data as SBIR/STTR funding decisions are being finalized.

Companies are encouraged to review ADDF's current funding priorities for drug development and neuroimaging and CSF biomarkers and apply to the appropriate RFP in our Therapeutics funding programs following the application instructions.

2. Additionally, the ADDF will consider funding for relevant grant applications from academic groups and biotech companies that were submitted to the NIA or the NINDS and were scored but not funded. The proposed work should fall within the ADDF’s mission and current funding priorities for drug developmentprevention, and neuroimaging and CSF biomarkers. Please email aburstein@alzdiscovery.org with a brief summary of your project. If invited to submit a full proposal, eligible investigators may submit their original NIA or NINDS applications and a copy of the study section review.

 

 

Eligibility

Faculty

Category

Medical
Medical - Clinical Science
Medical - Translational